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Objective: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many
treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for
personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to
tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort.
Methods and materials: EuroTARGET is a European collaborative project designed as an observational study for which patients with
mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed
clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline
DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor
DNA, RNA, kinome, and methylome analyses.
Results: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted
treatment (sunitinib [N ¼ 713, 78%], sorafenib [N ¼ 41, 4%], or pazopanib [N ¼ 166, 18%]) and had at least 6 months of outcome
assessment (median follow-up 15.3 months [interquartile range: 8.5–30.2 months]). Germline DNA samples were available from 824 of
these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays
created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were
successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of
germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and processed
for 121 patients (PamChip), and methylome data (Illumina Infinium HumanMethylation450 BeadChip) were created for 116 RCC tissues
(and 23 normal kidney tissues). For 73 out of the 920 patients, all platform data types were generated. In addition, 40 patients were included
in a pharmacokinetic/pharmacodynamic phase IV substudy.
Conclusions: Analysis of EuroTARGET cohort data will contribute to personalization of therapy for patients with mRCC. The extensive
clinical data and multiplatform EuroTARGET data will be freely available. r 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Metastatic renal cell carcinoma; Therapy response; Tyrosine kinase inhibitor; Biomarker; Transcriptomics; Genomics1. Introduction
With more than 121,000 newly diagnosed patients and
52,000 deaths each year, kidney cancer is the seventh most
common cancer in Europe [1]. Further, 90% of all kidney
cancers are renal-cell carcinomas (RCC). The prognosis of
RCC is highly dependent on stage. Surgery is effective for
the 70% to 80% of patients with localized disease, leading
to 5-year relative survival rates of more than 70% [2].
However, 25% of patients have metastatic RCC (mRCC)
at first diagnosis, and 25% of patients with localized
disease develop metastases after surgery [3,4].
Until the arrival of tyrosine kinase inhibitors (TKIs),
treatment options in mRCC were limited, and 5-year
relative survival was only 5% to 10%. Randomized clinical
trials showed that TKI agents, directly targeting tumorigenic
and angiogenic pathways (reviewed in [5]), significantly
improved the outcomes of these patients [6]. Several first-
line TKI treatment options are now available, such as
sunitinib, pazopanib, or bevacizumab plus interferon-alpha
[6]. Most patients experience disease stabilization or
response for a median of 12 months [7]. However, TKI
treatment is extremely expensive (sunitinib was estimated in
the UK to cost £71,462 per quality adjusted life year gained
[8]), 15% to 20% of patients experience immediate disease
progression despite treatment [7], nearly all patients even-
tually become resistant, and toxicity is common and leads to
dose reduction. In addition, first-line treatment options for
patients with mRCC will likely increase in coming years
(including immune checkpoint inhibition) [9]. There is, hence,much interest in tools for prediction of individual therapy
response and acquired resistance to TKIs to optimize treat-
ment outcome while reducing unnecessary drug use and
expenses, and improving human health and quality of life.
Currently, treatment choice in mRCC is based on risk
grouping of patients by clinical parameters such as the
patientʼs performance status, and serum biochemical meas-
urements, and histological features of the tumor [10].
A comparison study into several clinical risk grouping
models, including that of the International Metastastic Renal
Cell Carcinoma Database Consortium [11] and the Memo-
rial Sloan Kettering Cancer Center (MSKCC) [12], showed
modest discriminatory values for survival (area under the
receiver operating curve 0.66) and indicated that addition
of tumor-specific or patient-specific biomarkers is likely
required for the improvement of the accuracy of these
models [13].
Advances in high-throughput technologies have paved
the way to personalized medicine using biomarkers. For
mRCC, potential prognostic molecular biomarkers such as
PBRM1, BAP1, and KDM5C tumor mutations [14]; IL8
[15], VEGF, and PlGF levels [16]; ABCB1 and VEGFR-3
germline polymorphisms [17]; and miRNA levels have
been identified [18,19]. However, there are no validated
biomarkers yet that can guide personalization of therapy in
patients with mRCC.
In this framework EuroTARGET was initiated, a “Euro-
pean collaborative project on TArgeted therapy in Renal
cell cancer: GEnetic and Tumor-related biomarkers for
response and toxicity.” The overarching goal of this
Table 1
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host and tumor-related biomarkers that can be used to
distinguish expected responders from nonresponders for
targeted therapy in mRCC. Here, we describe the cohort of
recruited patients, their characteristics, and the collected data.Sex
Eligibility criteria
Date of diagnosis metastasis
General information at diagnosis
Height
Bilateral renal cell carcinoma
Tumor assessment at start of treatment
cTNM classification
pTNM classification
Comorbidities at start of treatment of metastasis
Treatment line
Clinical data at start of treatment of metastasis
Number of locations and location of metastases







Final information on patient
Date of death
Last registration date
cTNM ¼ clinical tumor-nodes-metasasis; pTNM ¼ pathological
tumor-nodes-metasasis.2. Material and methods
2.1. Study design and patient recruitment
EuroTARGET is an international, multicenter observa-
tional study that started in March 2011. The study was
approved by the ethics committee at each participating
center. A total of 748 patients were recruited prospectively
in 62 centers; 36 in The Netherlands, 16 in Spain, 8 in
Germany, 1 in Romania, and 1 in the United Kingdom.
Patient identification and invitation procedures differed per
country (Supplementary material), but at all locations, the
following were the inclusion criteria: patients gave written
informed consent, were at least 18 years of age, and had
newly diagnosed metastatic renal-cell carcinoma. Patients
were enrolled in the study regardless of RCC subtype and
(pre)treatment.
In addition to the prospectively recruited patients, 462
patients with mRCC from previous studies (“historical
patients”) were included in EuroTARGET. Of these, 56
patients were retrospectively included in PERCEPTION, a
Dutch population-based study with patients diagnosed
between January 2008 and December 2010 [20]; 89 patients
were enrolled between October 2007 and December 2010
by the Spanish Oncology Genitourinary Group [21]; 153
patients were included between June 2004 and October
2010 by a Dutch working group of 6 university hospitals
focussing on sunitinib-induced toxicity [22]; and 35 patients
were recruited to a study on the epidemiology and
inheritance of renal cancer conducted by deCODE genetics
in Iceland since 2001 [23]. The Radboud university medical
center (Radboudumc) included another 66 patients, col-
lected in a prospective biobank of patients diagnosed with
cancer. The Central European Society for Anticancer Drug
Research included an extra 63 patients, collected in
prospective biobanks from Saarland University Medical
Center in Homburg, Germany, Jena University Hospital in
Germany, and University Hospital Graz in Austria. All
biobanks were approved by the local ethics committees
(Supplementary material).
2.2. Collection of clinical data
Clinical information from all patients was collected by
medical file review and entered in web-based case record
forms (CRFs) (Supplementary material and Table 1). All data
were managed, exchanged cross-border, and used according
to the data protection laws in Europe. Data included
demographic information, baseline clinical characteristics,treatment lines, drug toxicities (Common Terminology
Criteria for Adverse Events [CTCAE version 4.0] Z 3),
tumor response (i.e., Complete remission, partial remission,
stable disease, or progressive disease), and death. Tumor
response was defined according to RECIST version 1.1 and
based on patient evaluation by local caregivers as given in
the radiology report or medical record (no review of
imaging).
Clinical data were extracted from the web-based CRFs
and checked for missing and inconsistent data. Both were
resolved where possible by looking deeper into the CRF
information or by going back to the medical files
(Supplementary material). End points for efficacy and
toxicity analyses, including progression-free survival
(PFS) time, overall survival (OS) time, dose reductions,
dose interruptions, and grade 3 or higher toxicities, were
calculated from the clinical data using algorithms
(Supplementary material).
2.3. Collection of biomaterials
Blood samples were collected from almost all patients
for germline DNA isolation. In 12 German and Dutch
centers, up to 12 plasma samples were collected per patient
before and during sunitinib or pazopanib treatment, for
measurement of drug and metabolite concentrations. In
addition, tumor material from the kidney and normal kidney
tissue was collected during nephrectomy if possible, and
freshly frozen. This fresh-frozen material was mainly
Fig. 1. Flowchart describing the selection of EuroTARGET patients for
future analyses.
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Paraffin-embedded tumor material from the kidney was
not collected specifically for EuroTARGET, but it was
collected from patients with histologically confirmed RCC
at the local pathology departments. Slides were collected for
central pathology review of tumor subtype and histopatho-
logical features by one of the four expert uropathologists
from Spain, The Netherlands, Germany, and the United
Kingdom. In The Netherlands, paraffin-embedded material
was also used to construct tissue microarrays (TMAs)
containing three 3 mm cores from representative tumor
areas per patient. Blood or DNA samples or both and
freshly frozen samples were coded and stored at the
central EuroTARGET biobank at the Radboudumc, The
Netherlands.Table 2
Origin of the EuroTARGET patient population
All collected patients Patients to be included in2.4. Platform and pharmacokinetic/pharmacodynamic
analyses
EuroTARGET encompasses multiplatform omics profil-
ing and pharmacokinetic/pharmacodynamic (PK/PD) anal-
yses. Genome-wide germline DNA variation data were
measured using Illumina HumanOmniExpress BeadChips.
Tumor material was profiled using next-generation whole-
exome sequencing (Illumina; tumor DNA and matched
germline DNA), RNA sequencing (Illumina), PamChip
kinase assays, and Illumina Infinium HumanMethyla-
tion450 BeadChips. PK/PD models were developed using
NONMEM 7.3 software.analyses


















SOGUG 89 872.5. Availability of data
All clinical and platform data generated in EuroTAR-
GET will be made freely available in an anonymized way
for the research community as of March 2018. The data can
be accessed through the European Genome-phenome
Archive (EGA) which is the controlled access repository
under the European Bioinformatics Institute (EMBL-EBI).
Interested parties will be able to find the EuroTARGET











Total 748 462 523 397
CESAR ¼ Central European Society for Anticancer Drug Research;
PERCEPTION = Dutch population-based registry of mRCC patients;
SOGUG ¼ Spanish Oncology Genitourinary Group; SUTOX ¼ Dutch
working group of six university hospitals focussing on sunitinib-induced
toxicity.3. Results
In total, 1,210 patients with mRCC were included in
EuroTARGET, of which 748 were collected prospectively
and 462 were available from historical (prospective) series
at the start of EuroTARGET. Of the 1,210 patients, we
selected the 979 patients (81%) who received sunitinib,
sorafenib, or pazopanib as first TKI (remainder of patients
did, for example, have no treatment or were treated with an
mTOR inhibitor or other TKI). Prior cytokine therapy was
allowed. To enable informative future analyses, we only
focus on the subset of 920 patients for whom outcome
could be assessed for at least 6 months (24 weeks) (Fig. 1).Table 2 displays the origin of the 1,210 patients collected
for EuroTARGET and of the 920 patients who were
selected as being relevant for future analyses.3.1. Baseline characteristics
Baseline characteristics of the total patient population strati-
fied by first-line TKI are shown in Table 3 (see Tables S1a and
S1b in supplementary material for baseline characteristics
Table 3
Baseline characteristics of the EuroTARGET patient population
All patients Sunitinib Sorafenib Pazopanib
N ¼ 920 N ¼ 713 N ¼ 41 n ¼ 166
Median age at start TKI, y 64 63 61 66
Range 20–87 20–87 45–82 40–84
Sex
Male 663 (72.1%) 525 (73.6%) 32 (78.0%) 106 (63.9%)
Female 257 (27.9%) 188 (26.4%) 9 (22.0%) 60 (36.1%)
No. of metastases at start TKI
1 323 (35.1%) 268 (37.6%) 12 (29.3%) 43 (25.9%)
2 324 (35.2%) 248 (34.8%) 16 (39.0%) 60 (36.1%)
3 or more 270 (29.3%) 195 (27.3%) 12 (29.3%) 63 (38.0%)
Unknown 3 (0.3%) 2 (0.3%) 1 (2.4%)
Sites of metastases, n (%)
Lung 634 (68.9%) 487 (68.3%) 33 (80.5%) 114 (68.7%)
Lymph node 394 (42.8%) 289 (40.5%) 22 (53.7%) 81 (48.8%)
Bone 258 (28.0%) 203 (28.5%) 8 (19.5%) 47 (28.3%)
Liver 163 (17.7%) 123 (17.3%) 6 (14.6%) 34 (20.5%)
WHO performance status
0 323 (35.1%) 259 (36.3%) 11 (26.8%) 53 (31.9%)
1 347 (37.7%) 277 (38.8%) 7 (17.1%) 63 (38.0%)
2 48 (5.2%) 28 (3.9%) 1 (2.4%) 19 (11.4%)
3 7 (0.8%) 4 (0.6%) 3 (1.8%)
4 1 (0.1%) 1 (0.1%)
Unknown 194 (21.1%) 144 (20.2%) 22 (53.7%) 28 (16.9%)
IMDC risk stratification
Favorable risk 74 (8.0%) 65 (9.1%) 3 (7.3%) 6 (3.6%)
Intermediate risk 232 (25.2%) 188 (26.4%) 3 (7.3%) 41 (24.7%)
Poor risk 169 (18.4%) 134 (18.8%) 6 (14.6%) 29 (17.5%)
Unknowna 445 (48.4%) 326 (45.7%) 29 (70.7%) 90 (54.2%)
Prior nephrectomy 690 (75.0%) 534 (74.9%) 28 (68.3%) 128 (77.1%)
Cytokine therapy before TKI 54 (5.9%) 39 (5.5%) 14 (34.1%) 1 (0.6%)
Histology subtypeb
Clear cell 802 (87.2%) 620 (87.0%) 34 (82.9%) 148 (89.2%)
Non-clear cell 78 (8.5%) 66 (9.3%) 2 (4.9%) 10 (6.0%)
Unknown 40 (4.3%) 27 (3.8%) 5 (12.2%) 8 (4.8%)
Material available
DNA 824 (89.6%) 650 (91.2%) 28 (68.3%) 146 (88.0%)
RCC tissue 142 (15.4%) 113 (15.8%) 15 (36.6%) 14 (8.4%)
Normal kidney tissue 95 (10.3%) 75 (10.5%) 8 (19.5%) 12 (7.2%)
TMA 247 (26.8%) 193 (27.1%) 16 (39.0%) 38 (22.9%)
TMA ¼ tissue microarray; IMDC ¼ International Metastastic Renal Cell Carcinoma Database Consortium; WHO ¼ World Health Organization.
aIMDC risk stratification was unknown if one of the criteria to determine the risk was missing
bFor histology subtype, we used the subtype defined by a central pathologist. If subtype was not determined by a central pathologist, we used subtype
defined by a local pathologist. See Table S2 in the supplementary material for more information.
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patients from historical series).3.2. Follow-up data
Patient follow-up was completed up to March 1, 2016, and
censored at this date if patients were still alive, which was the
case for 241 patients (26%). A total of 478 patients (52%) were
followed until their death. For 39 patients (4%), date of death
was known, but follow-up was not completed up to the date of
death. For another 162 patients (18%), follow-up information
was not complete up to March 1, 2016, nor was date of death
known. These patients were censored at the last date registeredin the CRF. Median follow-up time from start of TKI treatment
until death or censoring for all patients was 15.3 months
(interquartile range [IQR]: 8.5–30.2 months).
Progression is defined as relapse or progressive disease,
development of a new lesion, or death. We calculated PFS
time as the time between start of TKI treatment and date of
progression, death, or censoring (whichever happened first),
regardless of duration of TKI treatment. OS time was
calculated as the time between start of TKI treatment and
date of death or censoring. A total of 681 patients (74%)
experienced a progression event and 517 (56%) died during
follow-up. Median PFS time was 10.8 months (IQR: 4.4–
24.6 months) and median OS was 26.1 months (IQR: 10.6–
51.3 months) (Fig. 2).
Fig. 2. Kaplan-Meier curves for progression-free survival (A) and overall survival (B). Vertical lines indicate censoring events.
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patients were actually using TKI treatment (sunitinib,
sorafenib, or pazopanib). In this scenario, patients were
censored when they stopped TKI treatment, and PFS time
was calculated as the time between start of TKI treatment
and progression, death, or censoring (whichever came first).
With this definition, 546 patients (59%) experienced a
progression event, and median PFS time was 11.7 months
(IQR: 5.0–30.1 months).
Table 4 shows the follow-up characteristics of the total
patient population and separately for the different first-line
TKIs used (see Supplementary Tables S3a and S3b for
follow-up characteristics for the prospectively recruited and
historical patients).3.3. Biomaterial and platform data
Germline DNA was available from 824 of 920 patients
and fresh-frozen tissue from 145 patients (primary kidney
tumor, N ¼ 142; normal kidney, N ¼ 95). TMAs wereTable 4






Median follow-up time, mo 15.3
Follow-up until progression event
Yes 681 (74%)
No 239 (26%)
Median PFS time, moa 10.8
Follow-up until progression event while on TKI
Yes 546 (59%)
No 374 (41%)
Median PFS time while being on TKI, monthsa 11.7
aPlease note that in “Median PFS time,” progression events after stopping T
treatment and event was long. In “median PFS time while being on TKI,” patient
that occur shortly after TKI treatment stop are not taken into account.created from 247 patients. Platform data were successfully
generated for the following number of patients (out of
the 920): germline DNA variation chip data for 811,
whole-exome sequencing data (tumor and germline DNA)
for 80, RNAseq data (tumor mRNA and miRNA) for 124,
processed kinase activity data for 121, and methylation data
for 116 RCC tissues (and 23 normal kidney tissues). For 73
patients, all platform data are available. PK/PD data are
available from 40 patients.4. Discussion
EuroTARGET is a European collaborative project,
which aims to discover and validate biomarkers to person-
alize treatment of patients with mRCC. Here, we describe
the EuroTARGET patient population, a large, extensively
phenotyped cohort of 920 patients with mRCC with most
patients receiving sunitinib as first-line TKI. For most
patients, genome-wide germline DNA variation data are
available, making this the largest cohort for prognosticSunitinib Sorafenib Pazopanib
N ¼ 713 N ¼ 41 n ¼ 166
420 (59%) 24 (59%) 73 (44%)
293 (41%) 17 (42%) 93 (56%)
17.0 13.7 12.9
534 (75%) 32 (78%) 115 (69%)
179 (25%) 9 (22%) 51 (31%)
11.1 7.6 10.6
441 (62%) 26 (63%) 79 (48%)
272 (38%) 15 (37%) 87 (52%)
12.5 8.1 12.0
KI treatment are considered as events, even when time between stop of
s are censored at the moment they stop TKI treatment meaning that events
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patients with mRCC. For 73 patients, germline genome,
tumor genome, transcriptome, kinome activity, as well as
methylome data are available, allowing for an integrated
analysis of multiplatform data.
In recent years, a number of renal cancer biorepositories
with extended platform data have been generated. For
example, the International Cancer Genome Consortium
(https://icgc.org/), including, among others, The Cancer
Genome Atlas Project [24], has profiled more than 1,200
patients with renal cancer at the DNA, RNA, protein, and
epigenetics level. These data have been very valuable for
insight into the existence of molecular subtypes [25].
However, the number of patients with mRCC and clinical
data is limited, restricting the value of these data for
prognostic biomarker studies in mRCC. Indeed, potentially
relevant prognostic biomarkers for mRCC have, to date,
mainly been derived from (randomized) clinical trials
[14,18].
In contrast to clinical trial biorepositories with strict
inclusion and exclusion criteria, EuroTARGET is of an
observational nature. Therefore, patients should be more
reflective of the general TKI population and results better
generalizable. However, it also has disadvantages such as
the dependence on information that is registered in medical
files for information retrieval. Also, more than 60 centers
and 5 European countries were involved in patient recruit-
ment, resulting in a number of challenges. For example, the
start of patient recruitment was severely delayed because of
difficulties in obtaining ethical approval for this observa-
tional study that was erroneously regarded as a clinical trial
by many of the recruitment centers.
Inclusion of patients from historical series in Euro-
TARGET substantially increased the number of available
patients. It also poses some concerns, as these patients were
sampled for projects with different aims, in different time
periods, and using different inclusion procedures. For
instance, we observed a median PFS and OS time of 8.9
and 20.7 months in the historical patient series compared to
11.8 and 30.3 months in the prospectively recruited
patients, possibly reflecting improvement in mRCC treat-
ment over time. Although biomarkers can be identified
regardless of this, the quantitative effect estimate of the
biomarker may not be representative for all current patients
with mRCC.
The importance of replication and validation of bio-
marker findings has been stressed in many publications
[26]. The original objective of EuroTARGET was to
perform a two-stage inclusion of patients and samples to
allow for both a discovery and a replication cohort within
the consortium. However, owing to recruitment difficulties,
the distinction between discovery and replication cohort has
been abandoned. Instead, we will use external mRCC
patient cohorts for replication [27–29]. Also note that
functional validation of biomarker findings using, forexample, in vitro studies in established RCC cell lines are
integral parts of EuroTARGET.
Currently, analyses of clinical and platform data (sepa-
rately and integrated), PK/PD analyses, and functional
studies are ongoing within the EuroTARGET consortium.
We hereby hope to improve understanding of the critical
molecular and resistance pathways involved in TKI therapy
and to define new validated risk stratification criteria to be
used in personalized mRCC patient management.5. Conclusions
EuroTARGET is a European collaborative project
including 920 patients with mRCC treated with sunitinib,
sorafenib, or pazopanib. EuroTARGET data will be freely
available from March 1, 2018. We hope that easy access
will promote the uptake of EuroTARGET data by the
research community, and thereby the progress in person-
alization of therapy for patients with mRCC.Acknowledgments
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